EXEL vs TXG
Exelixis vs 10x Genomics, Inc. — AI-powered side-by-side comparison
VS
TXG
10x Genomics, Inc.
53
Watch
| Metric | EXEL | TXG |
|---|
| AI Score |
67
|
53
|
| Price |
$51.30
|
$58.48
|
| P/E Ratio |
15.60×
|
-99.12×
|
| ROE |
36.2%
|
-5.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
70.0%
|
| Debt / Equity |
0.09×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
79.3
|
| Beta |
0.422
|
2.039
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TXG.
EXEL leads by 14 points.
EXEL scores 67/100 (Buy) versus TXG at 53/100 (Watch).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TXG Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -4.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- RSI at 79 is in overbought territory — Technical